Reuters logo
BRIEF-Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugs
November 14, 2017 / 12:29 PM / 6 days ago

BRIEF-Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugs

Nov 14 (Reuters) - Loxo Oncology Inc

* Loxo Oncology announces global development and commercialization partnership with Bayer for larotrectinib and LOXO-195

* Loxo Oncology Inc - ‍Loxo Oncology and Bayer to co-promote in U.S. with a 50/50 profit share; Bayer to commercialize RoW​

* Loxo Oncology Inc - ‍under terms of agreement, Loxo Oncology will receive a $400 million upfront payment​

* Loxo Oncology Inc - deal includes ‍up to $1.55 billion in upfront, regulatory, and commercial milestones​

* Loxo Oncology - co eligible for $450 million in milestone payments upon larotrectinib approvals, first commercial sale events in some markets​

* Loxo Oncology - co also eligible for additional $200 million in payments upon LOXO-195 approvals, first commercial sale events in some markets​

* Loxo Oncology - ‍outside of U.S., ​Bayer will pay co royalties on sales, sales milestones totaling $475 million for larotrectinib & LOXO-195 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below